$0.31
(Market cap
$5,457 Mln
Recently Viewed
Clear AllMarket cap
$5,457 Mln
Revenue (TTM)
$1,542 Mln
P/E Ratio
24.6
P/B Ratio
5
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
14.2
Debt to Equity
0
Book Value
$16.4
EPS
$3.5
Face value
--
Shares outstanding
65,102,599
CFO
$936.70 Mln
EBITDA
$716.70 Mln
Net Profit
$474.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lantheus Holdings (LNTH)
| 23.0 | 7.1 | 23.2 | -18.6 | -3.3 | 30.6 | 46.1 |
|
BSE Sensex
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Lantheus Holdings (LNTH)
| -25.6 | 43.9 | 21.7 | 76.4 | 114.2 | -34.2 | 31.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lantheus Holdings (LNTH)
|
81.9 | 5,456.9 | 1,541.6 | 233.6 | 21.6 | 21.4 | 24.6 | 5.0 |
| 8.4 | 5,633.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 1.0 | |
| 277.0 | 7,476.3 | 2,583.2 | 759.9 | 25.2 | 10.8 | 9.9 | 1.0 | |
| 39.5 | 6,195.5 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.4 | |
| 27.3 | 4,414.8 | 2,719.5 | 47.0 | 8.4 | 1.6 | 96.2 | 1.4 | |
| 121.6 | 6,939.8 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.6 | |
| 178.4 | 9,341.0 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.6 | 12.9 | |
| 333.0 | 12,941.2 | 1,403.7 | 177.7 | 14.7 | 13.8 | 73 | 9.1 | |
| 129.2 | 7,400.2 | 738.3 | 48.9 | 11.4 | 2.4 | 150.8 | 3.5 | |
| 32.8 | 14,139.4 | 6,178.4 | 626.5 | 13.0 | 11.9 | 23.2 | 2.6 |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable... ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. Read more
CEO & Director
Mr. Brian A. Markison
CEO & Director
Mr. Brian A. Markison
Headquarters
Bedford, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Lantheus Holdings Inc (LNTH) is $81.88 (NASDAQ) as of 22-Apr-2026 11:39 EDT. Lantheus Holdings Inc (LNTH) has given a return of -3.33% in the last 3 years.
The P/E ratio of Lantheus Holdings Inc (LNTH) is 24.58 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.90
|
4.05
|
|
2024
|
19.82
|
5.69
|
|
2023
|
13.30
|
5.33
|
|
2022
|
124.37
|
7.81
|
|
2021
|
-27.44
|
4.21
|
The 52-week high and low of Lantheus Holdings Inc (LNTH) are Rs 108.91 and Rs 47.25 as of 22-Apr-2026.
Lantheus Holdings Inc (LNTH) has a market capitalisation of $ 5,457 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Lantheus Holdings Inc (LNTH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.